A comprehensive view of Gene Therapy & Regenerative Medicine. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer gains FDA approval for its gene therapy Beqvez for hemophilia B treatment, pricing it at US$3.5M, matching the cost of the world's most expensive drug, Hemgenix; the therapy aims to provide long-term benefits and potentially reduce costs
Published: April 26, 2024 by FiercePharma
Pfizer gains FDA approval for BEQVEZ, a one-time dose treatment for adults with moderate to severe hemophilia B; the treatment is currently under review in Europe and was recently approved in Canada
Published: April 26, 2024 by Pfizer Inc.
Regeneron partners with CRISPR drug developer Mammoth Biosciences to develop in vivo gene therapies; the US$100.0M deal combines Regeneron's viral vector technology with Mammoth's DNA editing platforms for 5.5 years, with option to extend
Published: April 25, 2024 by BioPharma Dive
Walgreens announces Specialty Pharmacy that incorporates AllianceRx with existing assets to increase access to treatments for chronic conditions; Walgreens is also investing in gene and cell therapy services and establishing a new Innovation Center
Published: April 25, 2024 by Walgreens Boots Alliance Inc.
'Tim-3 Antagonists For The Treatment And Diagnosis Of Cancers' in Patent Application Approval Process (USPTO 20240117044)
Published: April 25, 2024 by NewsRx Pharma Business Daily

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count